"Mid Atlantic Retina is an internationally recognized, pre-eminent retina practice in Pennsylvania, New Jersey and Delaware delivering state-of-the-art, comprehensive patient care for over 40 years. Our retina specialists are world-renowned and board-certified physicians with over 400 years of combined expertise. They are recognized as leaders in vitreoretinal diseases by ophthalmology and medical societies. We are dedicated to the diagnosis and treatment of retina, vitreous and macula disorders, with the goal of restoring and maintaining sight to improve the quality of life for our patients. See a Wills Eye Doctor in Philadelphia today."

During the past decade, Mid Atlantic Retina conducted 43 clinical trials. In the 10-year time frame, 43 clinical trials started and 9 clinical trials were completed, i.e. on average, 20.9% percent of trials that started reached the finish line to date. In the past 5 years, 19 clinical trials started and 9 clinical trials were completed. i.e. 47.4% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Mid Atlantic Retina" #1 sponsor was "Hoffmann-La Roche" with 8 trials, followed by "Gyroscope Therapeutics Limited" with 4 trials sponsored, "Wills Eye" with 4 trials sponsored, "Apellis Pharmaceuticals, Inc." with 3 trials sponsored and "Genentech, Inc." with 3 trials sponsored. Other sponsors include 20 different institutions and companies that sponsored additional 23 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Mid Atlantic Retina" #1 collaborator was "Mid Atlantic Retina" with 4 trials as a collaborator, "Novartis Pharmaceuticals" with 4 trials as a collaborator, "AbbVie" with 1 trials as a collaborator, "Alcon Research" with 1 trials as a collaborator and "Chugai Pharmaceutical" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 7 trials.

According to Clinical.Site data, the most researched conditions in "Mid Atlantic Retina" are "Geographic Atrophy" (10 trials), "Macular Degeneration" (7 trials), "Diabetic Macular Edema" (5 trials), "Dry Age-related Macular Degeneration" (4 trials) and "Macular Edema" (3 trials). Many other conditions were trialed in "Mid Atlantic Retina" in a lesser frequency.

Most popular intervention types in "Mid Atlantic Retina" are "Drug" (38 trials), "Other" (12 trials), "Device" (4 trials), "Procedure" (4 trials) and "Biological" (2 trials). Other intervention types were less common.

The name of intervention was led by "Sham Procedure" (10 trials), "Aflibercept" (3 trials), "Faricimab" (3 trials), "KSI-301" (3 trials) and "Lampalizumab" (3 trials). Other intervention names were less common.

The vast majority of trials in "Mid Atlantic Retina" are 47 trials for "All" genders.

Currently, there are NaN active trials in "Mid Atlantic Retina". undefined are not yet recruiting, 6 are recruiting, 14 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 15 completed trials in Mid Atlantic Retina, undefined suspended trials, and 11 terminated clinical trials to date.

Out of the total trials that were conducted in Mid Atlantic Retina, 7 "Phase 1" clinical trials were conducted, 14 "Phase 2" clinical trials and 18 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 5 trials that are defined as “Not Applicable".